Immune checkpoint inhibitors in cervical cancer: Current status and research progress

Cervical cancer is the second most common gynecological malignant tumor endangering the health of women worldwide. Despite advances in the therapeutic strategies available to treat cervical cancer, the long-term prognosis of patients with recurrent and metastatic cervical cancer remains unsatisfacto...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yunkai, Kong, Weimin, Zhao, Xiaoling, Zhang, He, Luo, Dan, Chen, Shuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647018/
https://www.ncbi.nlm.nih.gov/pubmed/36387196
http://dx.doi.org/10.3389/fonc.2022.984896
_version_ 1784827292073066496
author Xie, Yunkai
Kong, Weimin
Zhao, Xiaoling
Zhang, He
Luo, Dan
Chen, Shuning
author_facet Xie, Yunkai
Kong, Weimin
Zhao, Xiaoling
Zhang, He
Luo, Dan
Chen, Shuning
author_sort Xie, Yunkai
collection PubMed
description Cervical cancer is the second most common gynecological malignant tumor endangering the health of women worldwide. Despite advances in the therapeutic strategies available to treat cervical cancer, the long-term prognosis of patients with recurrent and metastatic cervical cancer remains unsatisfactory. In recent years, immune checkpoint inhibitors (ICIs) have shown encouraging efficacy in the treatment of cervical cancer. ICIs have been approved for use in both first- and second-line cervical cancer therapies. This review summarizes the current knowledge of ICIs and the application of ICIs in clinical trials for the treatment of cervical cancer.
format Online
Article
Text
id pubmed-9647018
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96470182022-11-15 Immune checkpoint inhibitors in cervical cancer: Current status and research progress Xie, Yunkai Kong, Weimin Zhao, Xiaoling Zhang, He Luo, Dan Chen, Shuning Front Oncol Oncology Cervical cancer is the second most common gynecological malignant tumor endangering the health of women worldwide. Despite advances in the therapeutic strategies available to treat cervical cancer, the long-term prognosis of patients with recurrent and metastatic cervical cancer remains unsatisfactory. In recent years, immune checkpoint inhibitors (ICIs) have shown encouraging efficacy in the treatment of cervical cancer. ICIs have been approved for use in both first- and second-line cervical cancer therapies. This review summarizes the current knowledge of ICIs and the application of ICIs in clinical trials for the treatment of cervical cancer. Frontiers Media S.A. 2022-10-27 /pmc/articles/PMC9647018/ /pubmed/36387196 http://dx.doi.org/10.3389/fonc.2022.984896 Text en Copyright © 2022 Xie, Kong, Zhao, Zhang, Luo and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xie, Yunkai
Kong, Weimin
Zhao, Xiaoling
Zhang, He
Luo, Dan
Chen, Shuning
Immune checkpoint inhibitors in cervical cancer: Current status and research progress
title Immune checkpoint inhibitors in cervical cancer: Current status and research progress
title_full Immune checkpoint inhibitors in cervical cancer: Current status and research progress
title_fullStr Immune checkpoint inhibitors in cervical cancer: Current status and research progress
title_full_unstemmed Immune checkpoint inhibitors in cervical cancer: Current status and research progress
title_short Immune checkpoint inhibitors in cervical cancer: Current status and research progress
title_sort immune checkpoint inhibitors in cervical cancer: current status and research progress
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647018/
https://www.ncbi.nlm.nih.gov/pubmed/36387196
http://dx.doi.org/10.3389/fonc.2022.984896
work_keys_str_mv AT xieyunkai immunecheckpointinhibitorsincervicalcancercurrentstatusandresearchprogress
AT kongweimin immunecheckpointinhibitorsincervicalcancercurrentstatusandresearchprogress
AT zhaoxiaoling immunecheckpointinhibitorsincervicalcancercurrentstatusandresearchprogress
AT zhanghe immunecheckpointinhibitorsincervicalcancercurrentstatusandresearchprogress
AT luodan immunecheckpointinhibitorsincervicalcancercurrentstatusandresearchprogress
AT chenshuning immunecheckpointinhibitorsincervicalcancercurrentstatusandresearchprogress

Ejemplares similares